Scientists discover hidden differences among cells that may help them evade drug therapy

University of Maryland researchers have discovered that seemingly identical cells can use different protein molecules to carry out the same function in an important cellular process. The scientists named this newly discovered variability “functional mosaicism,” and it has significant implications for the development of therapeutic treatments, which are often designed Continue Reading

Brain cells that suppress drug cravings may be the secret to better addiction medicines

For the nearly 20 million U.S. adults who are addicted to drugs or alcohol, no effective medical treatment exists—despite plentiful scientific knowledge surrounding the factors that trigger relapse. It’s a quandary that prompted a research quest for Nobuyoshi Suto, Ph.D., of Scripps Research’s Department of Neuroscience. Rather than continue to Continue Reading

New drug may protect against memory loss in Alzheimer’s disease

A new drug discovered through a research collaboration between the University at Buffalo and Tetra Therapeutics may protect against memory loss, nerve damage and other symptoms of Alzheimer’s disease. Preclinical research found that the drug—called BPN14770—deters the effects of amyloid beta, a hallmark protein of Alzheimer’s that is toxic to Continue Reading

Researchers uncover how popular drug helps in heart failure

Results were released today from the first two clinical studies designed specifically to examine the effects of the heart drug sacubitril/valsartan on the structure and function of the failing heart. Treatment with sacubitril/valsartan, a combination angiotensin receptor-neprilysin inhibitor (ARNI), substantially lowers rates of death and hospitalization in certain types of Continue Reading

New drug combination shows promising activity in non-small cell lung cancer patients

Patients with non-small cell lung cancer (NSCLC) now have more improved treatment options compared to standard of care with the addition of several new agents called immune-checkpoint inhibitors (ICI). Despite these changes, many patients still develop progressive disease after ICI treatment. In a new study published in Clinical Cancer Research, Continue Reading

Modified drug combination may reduce risk of recurrence for some breast cancer patients

Oncologists at VCU Massey Cancer Center were invited to co-author an editorial published in the Journal of Clinical Oncology providing expert commentary on findings from a large study conducted by German investigators that a modified drug combination may lead to a decreased chance of disease recurrence for women with high Continue Reading

Novel paradigm in drug development

Traditional medicines mostly function as inhibitors, attacking the disease-relevant proteins that cause cancer, by binding to their accessible pockets. Following this strategy, only ~20% of all proteins are chemically addressable, leaving some of the most relevant targets inaccessible to therapeutic development. Targeted protein degradation (TPD) is a novel approach in Continue Reading

Alzheimer’s drug reverses brain damage from adolescent alcohol exposure in rats

A drug used to slow cognitive decline in adults with Alzheimer’s disease appears to reverse brain inflammation and neuron damage in rats exposed to alcohol during adolescence. In a study described in the journal Scientific Reports, Duke Health researchers sought to understand how intermittent binge drinking changes the hippocampus—a region Continue Reading